董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ivan Tornos | 男 | Chairman,President, Chief Executive Officer and Director | 49 | 1499.29万美元 | 25.96 | 2025-07-01 |
| Sreelakshmi Kolli | 女 | Director | 50 | 39.57万美元 | 0.58 | 2025-07-01 |
| Maria Teresa Hilado | 女 | Director | 60 | 32.26万美元 | 0.96 | 2025-07-01 |
| Syed Jafry | 男 | Director | 61 | 37.52万美元 | 1.32 | 2025-07-01 |
| Devdatt Kurdikar | 男 | Director | 56 | 12.38万美元 | 0.04 | 2025-07-01 |
| Louis A. Shapiro | 男 | Director | 65 | 37.04万美元 | 0.11 | 2025-07-01 |
| Betsy J. Bernard | 女 | Director | 70 | 34.83万美元 | 3.55 | 2025-07-01 |
| Arthur J. Higgins | 男 | Director | 69 | 34.61万美元 | 3.63 | 2025-07-01 |
| Robert A. Hagemann | 男 | Director | 68 | 36.67万美元 | 3.60 | 2025-07-01 |
| Michael J. Farrell | 男 | Lead Independent Director | 53 | 34.84万美元 | 1.70 | 2025-07-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ivan Tornos | 男 | Chairman,President, Chief Executive Officer and Director | 49 | 1499.29万美元 | 25.96 | 2025-07-01 |
| Sang Yi | 男 | Group President, Asia Pacific | 63 | 315.44万美元 | 24.94 | 2025-07-01 |
| Suketu Upadhyay | 男 | Chief Financial Officer and Executive Vice President - Finance, Operations and Supply Chain | 55 | 587.96万美元 | 22.89 | 2025-07-01 |
| Wilfred van Zuilen | 男 | Group President, Europe, Middle East and Africa | 55 | 348.38万美元 | 6.48 | 2025-07-01 |
| Lori Winkler | 女 | Senior Vice President, Chief Human Resources Officer | 63 | 未披露 | 未持股 | 2025-07-01 |
| Paul Stellato | 男 | Vice President, Controller and Chief Accounting Officer | 50 | 未披露 | 未持股 | 2025-07-01 |
| Rachel Ellingson | 女 | Senior Vice President and Chief Strategy Officer | 55 | 未披露 | 未持股 | 2025-07-01 |
| Mark Bezjak | 男 | President, Americas | 50 | 304.66万美元 | 5.70 | 2025-07-01 |
| Kevin Thornal | 男 | President, Global Businesses and the Americas | 51 | 未披露 | 未持股 | 2025-07-01 |
| Chad F. Phipps | 男 | Senior Vice President, General Counsel and Secretary | 53 | 322.76万美元 | 未持股 | 2025-07-01 |
董事简历
中英对照 | 中文 | 英文- Ivan Tornos
-
Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
Ivan Tornos,was appointed President and Chief Executive Officer and a member of the Board of Directors in August 2023. Previously, he served as the Company's Chief Operating Officer since March 2021, as Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the Company in November 2018 until December 2019. Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility. He has also served as a member of the board of directors at PHC Holdings Corporation since September 2021. - Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
- Ivan Tornos,was appointed President and Chief Executive Officer and a member of the Board of Directors in August 2023. Previously, he served as the Company's Chief Operating Officer since March 2021, as Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the Company in November 2018 until December 2019. Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility. He has also served as a member of the board of directors at PHC Holdings Corporation since September 2021.
- Sreelakshmi Kolli
-
Sreelakshmi Kolli，自2023年10月起担任直觉外科公司董事会成员。她目前是全球医疗器械公司Align Technology, Inc.（“Align”）的首席数字官。Kolli女士于2003年6月加入Align，在其任职期间担任过越来越多的职务，负责领导面向客户的应用程序的业务运营和工程。2012年12月晋升为信息技术副总裁，2018年2月晋升为全球信息技术高级副总裁，2020年4月晋升为高级副总裁、首席数字官。Kolli女士还是齐默巴奥米特控股公司的董事会成员。她是Salesforce.com执行顾问委员会的成员，也是旧金山大学信息技术董事会的外部顾问。Kolli女士在印度Trichy的Bharathidasan大学获得了物理学学士学位，并在国立理工学院获得了计算机应用硕士学位。她也是加州斯坦福商学院提供的斯坦福高管项目的毕业生。
Sreelakshmi Kolli,has been a member of Intuitive Surgical, Inc. Board of Directors since October 2023. She is currently chief digital officer of Align Technology, Inc. ("Align"), a global medical device company. Ms. Kolli joined Align in June 2003 and has held positions of increasing responsibility leading business operations and engineering for customer-facing applications during her tenure. She was promoted to vice president, information technology, in December 2012, to senior vice president, global information technology, in February 2018, and to senior vice president, chief digital officer, in April 2020. Ms. Kolli is also a member of the Board of Directors of Zimmer Biomet Holdings, Inc. She is a member of the Executive Advisory Board at Salesforce.com and an external advisor on the Board of Trustees Committee on Information Technology at the University of San Francisco. Ms. Kolli earned a B.S. in physics at Bharathidasan University and an M.S. in computer applications at the National Institute of Technology, both in Trichy, India. She is also a graduate of the Stanford Executive Program offered by the Stanford Graduate School of Business in California. - Sreelakshmi Kolli，自2023年10月起担任直觉外科公司董事会成员。她目前是全球医疗器械公司Align Technology, Inc.（“Align”）的首席数字官。Kolli女士于2003年6月加入Align，在其任职期间担任过越来越多的职务，负责领导面向客户的应用程序的业务运营和工程。2012年12月晋升为信息技术副总裁，2018年2月晋升为全球信息技术高级副总裁，2020年4月晋升为高级副总裁、首席数字官。Kolli女士还是齐默巴奥米特控股公司的董事会成员。她是Salesforce.com执行顾问委员会的成员，也是旧金山大学信息技术董事会的外部顾问。Kolli女士在印度Trichy的Bharathidasan大学获得了物理学学士学位，并在国立理工学院获得了计算机应用硕士学位。她也是加州斯坦福商学院提供的斯坦福高管项目的毕业生。
- Sreelakshmi Kolli,has been a member of Intuitive Surgical, Inc. Board of Directors since October 2023. She is currently chief digital officer of Align Technology, Inc. ("Align"), a global medical device company. Ms. Kolli joined Align in June 2003 and has held positions of increasing responsibility leading business operations and engineering for customer-facing applications during her tenure. She was promoted to vice president, information technology, in December 2012, to senior vice president, global information technology, in February 2018, and to senior vice president, chief digital officer, in April 2020. Ms. Kolli is also a member of the Board of Directors of Zimmer Biomet Holdings, Inc. She is a member of the Executive Advisory Board at Salesforce.com and an external advisor on the Board of Trustees Committee on Information Technology at the University of San Francisco. Ms. Kolli earned a B.S. in physics at Bharathidasan University and an M.S. in computer applications at the National Institute of Technology, both in Trichy, India. She is also a graduate of the Stanford Executive Program offered by the Stanford Graduate School of Business in California.
- Maria Teresa Hilado
-
Maria Teresa Hilado，担任全球制药公司Allergan plc的执行副总裁兼首席财务官（2014年12月至2018年2月退休）。在加入Allergan之前，Hilado女士从2009年到2014年担任百事可乐公司（PepsiCo Inc.）的财务高级副总裁和财务主管，负责全球运营项目，包括资本市场、资金管理、国际财务、养老金、保险以及全球采购资金。她此前曾担任Schering-Plough Corp.的副总裁兼财务主管（从2008年到2009年），也曾任职通用汽车公司（General Motors Co.）17年以上，担任领导职务，并不断增加责任，包括助理财务主管（从2006年到2008年）、GMAC Commercial Finance LLC的首席财务官（从2001年到2005年）。她的职业生涯始于菲律宾马尼拉的Far East Bank and Trust Co.。Hilado女士获得了菲律宾马尼拉雅典耀大学的管理工程学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
Maria Teresa Hilado served as Executive Vice President and Chief Financial Officer of Allergan plc, a global pharmaceutical company, from December 2014 until February 2018. Prior to joining Allergan, Ms. Hilado served as Senior Vice President, Finance and Treasurer of PepsiCo, Inc. from 2009 until 2014. She previoly served as Vice President and Treasurer for Schering Plough Corp. from 2008 to 2009 and spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including Assistant Treasurer and CFO, GMAC Commercial Finance. Ms. Hilado received a bachelor's degree in management engineering from Ateneo de Manila University in the Philippines, and a master of biness administration from the Darden School of Biness at the University of Virginia. - Maria Teresa Hilado，担任全球制药公司Allergan plc的执行副总裁兼首席财务官（2014年12月至2018年2月退休）。在加入Allergan之前，Hilado女士从2009年到2014年担任百事可乐公司（PepsiCo Inc.）的财务高级副总裁和财务主管，负责全球运营项目，包括资本市场、资金管理、国际财务、养老金、保险以及全球采购资金。她此前曾担任Schering-Plough Corp.的副总裁兼财务主管（从2008年到2009年），也曾任职通用汽车公司（General Motors Co.）17年以上，担任领导职务，并不断增加责任，包括助理财务主管（从2006年到2008年）、GMAC Commercial Finance LLC的首席财务官（从2001年到2005年）。她的职业生涯始于菲律宾马尼拉的Far East Bank and Trust Co.。Hilado女士获得了菲律宾马尼拉雅典耀大学的管理工程学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
- Maria Teresa Hilado served as Executive Vice President and Chief Financial Officer of Allergan plc, a global pharmaceutical company, from December 2014 until February 2018. Prior to joining Allergan, Ms. Hilado served as Senior Vice President, Finance and Treasurer of PepsiCo, Inc. from 2009 until 2014. She previoly served as Vice President and Treasurer for Schering Plough Corp. from 2008 to 2009 and spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including Assistant Treasurer and CFO, GMAC Commercial Finance. Ms. Hilado received a bachelor's degree in management engineering from Ateneo de Manila University in the Philippines, and a master of biness administration from the Darden School of Biness at the University of Virginia.
- Syed Jafry
-
Syed Jafry自2017年9月起担任Thermo Fisher Scientific Inc.地区高级副总裁兼总裁。他负责美国以外的所有业务地区。他于2005年3月加入Thermo Fisher Scientific，并在被任命为当前职位之前担任过许多职责不断增加的职务。Jafry先生的职业生涯始于伦敦的Glaxo Pharmaceuticals。加入Thermo Fisher Scientific之前，他在通用电气（General Electric）任职18年，在美国，荷兰，瑞士和中国担任商业，产品管理和一般管理职务，最近担任GE Sensing Asia总裁。Jafry先生拥有巴基斯坦拉合尔大学的机械工程学士学位，马萨诸塞大学的机械工程硕士学位和哈佛大学扩展学院的市场营销和管理硕士学位。
Syed Jafry,Senior Vice President and President, Regions of Thermo Fisher Scientific Inc. from September 2017 through his scheduled retirement announced for March 31 2022. Mr. Jafry is responsible for all business geographies outside the U.S. He joined Thermo Fisher Scientific in March 2005 and served in numerous roles of increasing responsibility prior to being appointed to his current position. Mr. Jafry started his career at Glaxo Pharmaceuticals in London. Prior to joining Thermo Fisher Scientific, he served for 18 years at General Electric, where he held commercial, product management and general management roles in the U.S., Netherlands, Switzerland and China, most recently serving as President of GE Sensing Asia. Mr. Jafry holds a Bachelor's degree in Mechanical Engineering from Lahore University in Pakistan, a Master's degree in Mechanical Engineering from the University of Massachusetts and a Master's certificate in Marketing and Management from Harvard University Extension School. - Syed Jafry自2017年9月起担任Thermo Fisher Scientific Inc.地区高级副总裁兼总裁。他负责美国以外的所有业务地区。他于2005年3月加入Thermo Fisher Scientific，并在被任命为当前职位之前担任过许多职责不断增加的职务。Jafry先生的职业生涯始于伦敦的Glaxo Pharmaceuticals。加入Thermo Fisher Scientific之前，他在通用电气（General Electric）任职18年，在美国，荷兰，瑞士和中国担任商业，产品管理和一般管理职务，最近担任GE Sensing Asia总裁。Jafry先生拥有巴基斯坦拉合尔大学的机械工程学士学位，马萨诸塞大学的机械工程硕士学位和哈佛大学扩展学院的市场营销和管理硕士学位。
- Syed Jafry,Senior Vice President and President, Regions of Thermo Fisher Scientific Inc. from September 2017 through his scheduled retirement announced for March 31 2022. Mr. Jafry is responsible for all business geographies outside the U.S. He joined Thermo Fisher Scientific in March 2005 and served in numerous roles of increasing responsibility prior to being appointed to his current position. Mr. Jafry started his career at Glaxo Pharmaceuticals in London. Prior to joining Thermo Fisher Scientific, he served for 18 years at General Electric, where he held commercial, product management and general management roles in the U.S., Netherlands, Switzerland and China, most recently serving as President of GE Sensing Asia. Mr. Jafry holds a Bachelor's degree in Mechanical Engineering from Lahore University in Pakistan, a Master's degree in Mechanical Engineering from the University of Massachusetts and a Master's certificate in Marketing and Management from Harvard University Extension School.
- Devdatt Kurdikar
-
Devdatt Kurdikar是Embecta的总裁兼首席执行官。此前，他曾担任BD公司糖尿病护理全球总裁。在此之前，他曾担任Cardiac Science Corporation（“CSC”）的总裁兼首席执行官，该公司是公共准入市场自动体外除颤器制造和营销的全球领导者。CSC通过破产程序被一家私募股权公司收购，在Kurdikar先生的领导下，CSC恢复了盈利增长，并成功出售给ZOLL Medical。在此之前，Kurdikar先生是Boston Scientific泌尿科和盆腔健康部门的男性健康副总裁兼总经理。他曾在American Medical Systems（“AMS”）担任相同的职务，并领导Men’s Health业务通过分拆和出售给Boston Scientific，在那里他领导业务通过整合到Boston Scientific。加入AMS之前，他曾担任Baxter International Inc.（“Baxter”）的营销副总裁，在那里他参与了推动市场准入的全球商业计划，并曾担任美国地区输液系统业务的营销副总裁。在他任职百特的11年里，Kurdikar先生在财务、战略和整合、研发计划和运营方面担任领导职务。他的职业生涯始于孟山都公司的高级研究工程师。Kurdikar拥有孟买大学（印度）化学工程学士学位。他获得Washington State大学的化学工程硕士学位，Purdue大学的化学工程博士学位，以及Washington大学的工商管理硕士学位。
Devdatt Kurdikar is the President and Chief Executive Officer of Embecta. Previoly, Mr. Kurdikar was the Worldwide President of Diabetes Care at BD. Prior to that role, Mr. Kurdikar was the President and CEO of Cardiac Science Corporation ("CSC"), a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Mr. Kurdikar's leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical. Prior to that role, Mr. Kurdikar was the Vice President and General Manager, Men's Health, within Urology and Pelvic Health at Boston Scientific. Mr. Kurdikar was in the same role at American Medical Systems ("AMS") and led the Men's Health biness through a carve out and sale to Boston Scientific, where Mr. Kurdikar led the biness through its integration into Boston Scientific. Before joining AMS, Mr. Kurdikar served as Vice President, Marketing, at Baxter, where he worked on a global commercial initiative to drive market access, and was previoly Vice President, Marketing, for the Infion Systems biness for the U.S. region. In his 11 years with Baxter, Mr. Kurdikar held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company. - Devdatt Kurdikar是Embecta的总裁兼首席执行官。此前，他曾担任BD公司糖尿病护理全球总裁。在此之前，他曾担任Cardiac Science Corporation（“CSC”）的总裁兼首席执行官，该公司是公共准入市场自动体外除颤器制造和营销的全球领导者。CSC通过破产程序被一家私募股权公司收购，在Kurdikar先生的领导下，CSC恢复了盈利增长，并成功出售给ZOLL Medical。在此之前，Kurdikar先生是Boston Scientific泌尿科和盆腔健康部门的男性健康副总裁兼总经理。他曾在American Medical Systems（“AMS”）担任相同的职务，并领导Men’s Health业务通过分拆和出售给Boston Scientific，在那里他领导业务通过整合到Boston Scientific。加入AMS之前，他曾担任Baxter International Inc.（“Baxter”）的营销副总裁，在那里他参与了推动市场准入的全球商业计划，并曾担任美国地区输液系统业务的营销副总裁。在他任职百特的11年里，Kurdikar先生在财务、战略和整合、研发计划和运营方面担任领导职务。他的职业生涯始于孟山都公司的高级研究工程师。Kurdikar拥有孟买大学（印度）化学工程学士学位。他获得Washington State大学的化学工程硕士学位，Purdue大学的化学工程博士学位，以及Washington大学的工商管理硕士学位。
- Devdatt Kurdikar is the President and Chief Executive Officer of Embecta. Previoly, Mr. Kurdikar was the Worldwide President of Diabetes Care at BD. Prior to that role, Mr. Kurdikar was the President and CEO of Cardiac Science Corporation ("CSC"), a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Mr. Kurdikar's leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical. Prior to that role, Mr. Kurdikar was the Vice President and General Manager, Men's Health, within Urology and Pelvic Health at Boston Scientific. Mr. Kurdikar was in the same role at American Medical Systems ("AMS") and led the Men's Health biness through a carve out and sale to Boston Scientific, where Mr. Kurdikar led the biness through its integration into Boston Scientific. Before joining AMS, Mr. Kurdikar served as Vice President, Marketing, at Baxter, where he worked on a global commercial initiative to drive market access, and was previoly Vice President, Marketing, for the Infion Systems biness for the U.S. region. In his 11 years with Baxter, Mr. Kurdikar held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.
- Louis A. Shapiro
-
Louis A. Shapiro，他于2006年10月加入HSS担任总裁兼首席执行官，并于2023年10月退休。在加入HSS之前，他从2002年到2006年在Geisinger Health System工作，担任越来越多的领导职务，并最终晋升为临床企业的执行副总裁兼首席运营官。从1999年到2002年，他担任McKinsey & Co.的高级医疗保健专家和顾问，并从1983年到1999年在其他医院和卫生系统担任职务。他还曾担任RightMove Health董事会的创始成员，Medical indemnity Assurance Company的总裁，以及the Greater New York Hospital Association的董事会主席，此外在他的职业生涯中还担任过许多其他董事会和顾问职位。他拥有Pittsburgh大学的心理学学士学位和Pittsburgh Graduate School of Public health大学的卫生管理硕士学位。
Louis A. Shapiro,joined HSS as its President and Chief Executive Officer in October 2006, retiring in October 2023. Prior to joining HSS, Mr. Shapiro worked at Geisinger Health System from 2002-2006, serving in roles with increasing leadership scope and ultimately advancing to Executive Vice President and Chief Operating Officer of the Clinical Enterprise. He served as a senior healthcare expert and consultant at McKinsey & Co. from 1999-2002 and held positions in other hospitals and health systems from 1983 through 1999. Mr. Shapiro also previously served as a founding member of the board of directors of RightMove Health, as President of Medical Indemnify Assurance Company, and as the Board Chair of the Greater New York Hospital Association, in addition to holding a number of other board and advisory roles over the course of his career. Mr. Shapiro has a bachelor of science degree in psychology from the University of Pittsburgh and a master's degree in health administration from the University of Pittsburgh Graduate School of Public Health. - Louis A. Shapiro，他于2006年10月加入HSS担任总裁兼首席执行官，并于2023年10月退休。在加入HSS之前，他从2002年到2006年在Geisinger Health System工作，担任越来越多的领导职务，并最终晋升为临床企业的执行副总裁兼首席运营官。从1999年到2002年，他担任McKinsey & Co.的高级医疗保健专家和顾问，并从1983年到1999年在其他医院和卫生系统担任职务。他还曾担任RightMove Health董事会的创始成员，Medical indemnity Assurance Company的总裁，以及the Greater New York Hospital Association的董事会主席，此外在他的职业生涯中还担任过许多其他董事会和顾问职位。他拥有Pittsburgh大学的心理学学士学位和Pittsburgh Graduate School of Public health大学的卫生管理硕士学位。
- Louis A. Shapiro,joined HSS as its President and Chief Executive Officer in October 2006, retiring in October 2023. Prior to joining HSS, Mr. Shapiro worked at Geisinger Health System from 2002-2006, serving in roles with increasing leadership scope and ultimately advancing to Executive Vice President and Chief Operating Officer of the Clinical Enterprise. He served as a senior healthcare expert and consultant at McKinsey & Co. from 1999-2002 and held positions in other hospitals and health systems from 1983 through 1999. Mr. Shapiro also previously served as a founding member of the board of directors of RightMove Health, as President of Medical Indemnify Assurance Company, and as the Board Chair of the Greater New York Hospital Association, in addition to holding a number of other board and advisory roles over the course of his career. Mr. Shapiro has a bachelor of science degree in psychology from the University of Pittsburgh and a master's degree in health administration from the University of Pittsburgh Graduate School of Public Health.
- Betsy J. Bernard
-
Betsy J. Bernard从2007年5月21日开始担任候补首席董事。Bernard女士从2002年10月到2003年12月担任 AT&T的总裁，她在该公司领导AT&T业务部的超过50000位雇员，之后是将近27 0亿美元的机构，其服务400万商业客户。她从2001年至2002年担任 AT&T消费者部门的首席执行官，该部门服务大约4000万消费者，并于2002年为AT&T贡献了115亿美元的常规收入。她担任消费者与小型业务分部的负责人，从2000年至2001年，担任Qwest Communications全国大众市场部的执行副总裁，并负责管理美国西部地区的所有零售市场，从1998年至2000年担任零售部的执行副总裁。
Betsy J. Bernard,President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford University's Sloan Fellowship Program. - Betsy J. Bernard从2007年5月21日开始担任候补首席董事。Bernard女士从2002年10月到2003年12月担任 AT&T的总裁，她在该公司领导AT&T业务部的超过50000位雇员，之后是将近27 0亿美元的机构，其服务400万商业客户。她从2001年至2002年担任 AT&T消费者部门的首席执行官，该部门服务大约4000万消费者，并于2002年为AT&T贡献了115亿美元的常规收入。她担任消费者与小型业务分部的负责人，从2000年至2001年，担任Qwest Communications全国大众市场部的执行副总裁，并负责管理美国西部地区的所有零售市场，从1998年至2000年担任零售部的执行副总裁。
- Betsy J. Bernard,President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford University's Sloan Fellowship Program.
- Arthur J. Higgins
-
Arthur J. Higgins，自2010年6月以来担任The Blackstone Group的顾问。在此之前，他于2006年1月至2010年5月间担任Bayer HealthCare AG的董事会主席，2004年7月至2010年5月间担任Bayer HealthCare Executive Committee的主席。此前，他曾于2001至2004年间担任Enzon Pharmaceuticals Inc.的董事长兼总裁。更早些时候，他效力于Abbott Laboratories长达14年之久，最近于1998至2001年间任其医药产品事业部总监。他是Pharmaceutical Research and Manufacturers of America PhRMA的前董事会成员，是国际制药商协会联合会（IFPMA）的前成员，也是欧洲制药工业协会联盟（EFPIA）的前主席。他是Ecolab Inc.和 Endo International plc的董事，也曾担任Resverlogix Corp.的董事。他毕业于苏格兰斯特拉斯克莱德大学，并获得生物化学理学学士学位。
Arthur J. Higgins,Operating Advisor to Abu Dhabi Investment Authority ("ADIA"), a sovereign globally-diversified wealth fund of the Government of the Emirate of Abu Dhabi. Prior to joining ADIA, Mr. Higgins served as Consultant to Blackstone Healthcare Partners of The Blackstone Group from June 2010 until June 2021. He also served as non-executive chairman of the board of Assertio Holdings, Inc., successor issuer to Assertio Therapeutics, Inc., from May 2020 until December 2020. Prior to that, he served as President, Chief Executive Officer and a member of the board of directors of Assertio Therapeutics, Inc. from March 2017 until its merger with Zyla Life Sciences in May 2020. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America ("PHRMA"), Council member of the International Federation of Pharmaceutical Manufacturers ("IFPMA") and President of the European Federation of Pharmaceutical Industries Association ("EFPIA"). He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry. - Arthur J. Higgins，自2010年6月以来担任The Blackstone Group的顾问。在此之前，他于2006年1月至2010年5月间担任Bayer HealthCare AG的董事会主席，2004年7月至2010年5月间担任Bayer HealthCare Executive Committee的主席。此前，他曾于2001至2004年间担任Enzon Pharmaceuticals Inc.的董事长兼总裁。更早些时候，他效力于Abbott Laboratories长达14年之久，最近于1998至2001年间任其医药产品事业部总监。他是Pharmaceutical Research and Manufacturers of America PhRMA的前董事会成员，是国际制药商协会联合会（IFPMA）的前成员，也是欧洲制药工业协会联盟（EFPIA）的前主席。他是Ecolab Inc.和 Endo International plc的董事，也曾担任Resverlogix Corp.的董事。他毕业于苏格兰斯特拉斯克莱德大学，并获得生物化学理学学士学位。
- Arthur J. Higgins,Operating Advisor to Abu Dhabi Investment Authority ("ADIA"), a sovereign globally-diversified wealth fund of the Government of the Emirate of Abu Dhabi. Prior to joining ADIA, Mr. Higgins served as Consultant to Blackstone Healthcare Partners of The Blackstone Group from June 2010 until June 2021. He also served as non-executive chairman of the board of Assertio Holdings, Inc., successor issuer to Assertio Therapeutics, Inc., from May 2020 until December 2020. Prior to that, he served as President, Chief Executive Officer and a member of the board of directors of Assertio Therapeutics, Inc. from March 2017 until its merger with Zyla Life Sciences in May 2020. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America ("PHRMA"), Council member of the International Federation of Pharmaceutical Manufacturers ("IFPMA") and President of the European Federation of Pharmaceutical Industries Association ("EFPIA"). He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry.
- Robert A. Hagemann
-
Robert A. Hagemann， Quest Diagnostics Incorporated的高级副总裁兼首席财务官，直到2013年7月退休。Hagemann先生于1992年加入Corning Life Sciences, Inc.（Quest Diagnostics的前母公司Corning的子公司），并在1998年被任命为Quest Diagnostics的首席财务官之前担任越来越重要的职务。加入Corning之前，他曾在Prime Hospitality， Inc.和Crompton & Knowles， Inc.担任高级财务职位。他还曾受雇于Arthur Young & Co. （Ernst & Young的前身公司）。他持有Rider大学的会计学士学位和Seton Hall大学的工商管理硕士学位。
Robert A. Hagemann,Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated until his retirement in July 2013. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics' former parent company, Corning Incorporated, in 1992 and held roles of increasing responsibility before being appointed Chief Financial Officer of Quest Diagnostics in 1998. Prior to joining Corning, Mr. Hagemann held senior financial positions at Prime Hospitality, Inc. and Crompton & Knowles, Inc. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University. - Robert A. Hagemann， Quest Diagnostics Incorporated的高级副总裁兼首席财务官，直到2013年7月退休。Hagemann先生于1992年加入Corning Life Sciences, Inc.（Quest Diagnostics的前母公司Corning的子公司），并在1998年被任命为Quest Diagnostics的首席财务官之前担任越来越重要的职务。加入Corning之前，他曾在Prime Hospitality， Inc.和Crompton & Knowles， Inc.担任高级财务职位。他还曾受雇于Arthur Young & Co. （Ernst & Young的前身公司）。他持有Rider大学的会计学士学位和Seton Hall大学的工商管理硕士学位。
- Robert A. Hagemann,Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated until his retirement in July 2013. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics' former parent company, Corning Incorporated, in 1992 and held roles of increasing responsibility before being appointed Chief Financial Officer of Quest Diagnostics in 1998. Prior to joining Corning, Mr. Hagemann held senior financial positions at Prime Hospitality, Inc. and Crompton & Knowles, Inc. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University.
- Michael J. Farrell
-
Michael J. Farrell，他一直担任ResMed董事（自2013年3月1日以来）。他一直担任ResMed的首席执行官和董事（2013年3月1日以来）。此前，他曾担任ResMed的美洲总裁（2011年5月以来）。他此前曾担任ResMed的战略业务单元的高级副总裁（从2007年7月到2011年5月）、ResMed的副总裁，负责美洲营销（从2005年6月到2007年7月），以及ResMed的副总裁，负责业务发展。他于2000年9月加入ResMed公司。此前，他曾担任Arthur D. Little、Genzyme Corporation、The Dow Chemical Company、BHP Billiton的管理咨询和生物技术、化工和钢铁制造业的职务。他任职于the La Jolla Playhouse和圣地亚哥the New Children's Museum的董事会。他持有新南威尔士大学的工程学士学位（一等荣誉）、麻省理工学院（Massachusetts Institute of Technology）的化学工程理学硕士学位，以及史隆管理学院 （ MIT Sloan School of Management）的工商管理硕士学位。
Michael J. Farrell,Chief Executive Officer of ResMed Inc. since March 2013 and Chairman of ResMed Inc. since January 2023. Prior to his appointment as Chief Executive Officer, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Sanofi Genzyme, Dow Chemical and BHP. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management. - Michael J. Farrell，他一直担任ResMed董事（自2013年3月1日以来）。他一直担任ResMed的首席执行官和董事（2013年3月1日以来）。此前，他曾担任ResMed的美洲总裁（2011年5月以来）。他此前曾担任ResMed的战略业务单元的高级副总裁（从2007年7月到2011年5月）、ResMed的副总裁，负责美洲营销（从2005年6月到2007年7月），以及ResMed的副总裁，负责业务发展。他于2000年9月加入ResMed公司。此前，他曾担任Arthur D. Little、Genzyme Corporation、The Dow Chemical Company、BHP Billiton的管理咨询和生物技术、化工和钢铁制造业的职务。他任职于the La Jolla Playhouse和圣地亚哥the New Children's Museum的董事会。他持有新南威尔士大学的工程学士学位（一等荣誉）、麻省理工学院（Massachusetts Institute of Technology）的化学工程理学硕士学位，以及史隆管理学院 （ MIT Sloan School of Management）的工商管理硕士学位。
- Michael J. Farrell,Chief Executive Officer of ResMed Inc. since March 2013 and Chairman of ResMed Inc. since January 2023. Prior to his appointment as Chief Executive Officer, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Sanofi Genzyme, Dow Chemical and BHP. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management.
高管简历
中英对照 | 中文 | 英文- Ivan Tornos
Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
Ivan Tornos,was appointed President and Chief Executive Officer and a member of the Board of Directors in August 2023. Previously, he served as the Company's Chief Operating Officer since March 2021, as Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the Company in November 2018 until December 2019. Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility. He has also served as a member of the board of directors at PHC Holdings Corporation since September 2021.- Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
- Ivan Tornos,was appointed President and Chief Executive Officer and a member of the Board of Directors in August 2023. Previously, he served as the Company's Chief Operating Officer since March 2021, as Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the Company in November 2018 until December 2019. Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility. He has also served as a member of the board of directors at PHC Holdings Corporation since September 2021.
- Sang Yi
Sang Yi，他被任命为亚太地区总裁并与2015年6月生效。他副总裁亚太地区产品的销售，营销和分销。他于2013年3月加入Zimmer，担任高级副总裁，负责亚太地区。加入Zimmer之前从2005年到2013年，他担任St. Jude Medical的副总裁和总经理，副总裁亚太地区和澳大利亚。此前，他担任Boston Scientific Corporation的各种领导职务超过10年，最后担任北亚副总裁。
Sang Yi,was appointed Group President, Asia Pacific, in March 2021. He is responsible for the sales, marketing and distribution of products, services and solutions in the Asia Pacific region. Mr. Yi joined the Company in March 2013 as Senior Vice President, Asia Pacific and was promoted to President, Asia Pacific, in June 2015. Prior to joining the Company, he served as Vice President and General Manager of St. Jude Medical for Asia Pacific and Australia from 2005 to 2013. Prior to that, Mr. Yi held several leadership positions over a ten-year period with Boston Scientific Corporation, ultimately serving as Vice President for North Asia.- Sang Yi，他被任命为亚太地区总裁并与2015年6月生效。他副总裁亚太地区产品的销售，营销和分销。他于2013年3月加入Zimmer，担任高级副总裁，负责亚太地区。加入Zimmer之前从2005年到2013年，他担任St. Jude Medical的副总裁和总经理，副总裁亚太地区和澳大利亚。此前，他担任Boston Scientific Corporation的各种领导职务超过10年，最后担任北亚副总裁。
- Sang Yi,was appointed Group President, Asia Pacific, in March 2021. He is responsible for the sales, marketing and distribution of products, services and solutions in the Asia Pacific region. Mr. Yi joined the Company in March 2013 as Senior Vice President, Asia Pacific and was promoted to President, Asia Pacific, in June 2015. Prior to joining the Company, he served as Vice President and General Manager of St. Jude Medical for Asia Pacific and Australia from 2005 to 2013. Prior to that, Mr. Yi held several leadership positions over a ten-year period with Boston Scientific Corporation, ultimately serving as Vice President for North Asia.
- Suketu Upadhyay
Suketu Upadhyay，于2023年8月被任命为首席财务官兼财务、运营和供应链执行副总裁。此前，他曾担任Zimmer Biomet Holdings， Inc.。自2019年7月加入公司以来，担任执行副总裁兼首席财务官。在加入Zimmer Biomet之前，Upadhyay先生于2016年11月至2019年6月担任Bristol-Myers Squibb Company的全球金融运营高级副总裁。在加入Bristol-Myers Squibb之前，他曾担任Endo International plc的执行副总裁兼首席财务官（2013年9月至2016年11月）。在任职Endo International之前，Upadhyay先生曾担任BD的临时首席财务官、财务高级副总裁、公司财务总监和首席会计官。在担任BD的临时首席财务官和公司财务总监之前，Upadhyay先生曾担任全球财务规划和分析高级副总裁，也曾担任BD国际业务的副总裁和首席财务官。在2010年加入BD之前，Upadhyay先生在AstraZeneca PLC和Johnson & Johnson担任多个领导职务。Upadhyay先生在KPMG的公共会计部门度过了他职业生涯的早期。他还担任Vertex Pharmaceuticals Incorporated的董事会成员（2022年5月以来）。
Suketu Upadhyay,Chief Financial Officer and Executive Vice President - Finance, Operations and Supply Chain of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, since July 2019;Senior Vice President, Global Financial Operations at Bristol-Myers Squibb from 2016 to June 2019;Executive Vice President and Chief Financial Officer of Endo International from 2013 to 2016;Previously served as interim Chief Financial Officer and Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of Becton Dickinson and Senior Vice President of Global Financial Planning and Analysis and Vice President and Chief Financial Officer of Becton Dickinson's international business;Previously held a number of global finance and strategy roles across AstraZeneca and Johnson & Johnson, including Research and Development, Supply Chain, Commercial Operations and Business Development;Spent the early part of his career in public accounting with KPMG, earning his CPA designation and his CMA designation (each designation currently inactive);Holds a Bachelor of Science in Finance from Albright College and an MBA from The Fuqua School of Business at Duke University.- Suketu Upadhyay，于2023年8月被任命为首席财务官兼财务、运营和供应链执行副总裁。此前，他曾担任Zimmer Biomet Holdings， Inc.。自2019年7月加入公司以来，担任执行副总裁兼首席财务官。在加入Zimmer Biomet之前，Upadhyay先生于2016年11月至2019年6月担任Bristol-Myers Squibb Company的全球金融运营高级副总裁。在加入Bristol-Myers Squibb之前，他曾担任Endo International plc的执行副总裁兼首席财务官（2013年9月至2016年11月）。在任职Endo International之前，Upadhyay先生曾担任BD的临时首席财务官、财务高级副总裁、公司财务总监和首席会计官。在担任BD的临时首席财务官和公司财务总监之前，Upadhyay先生曾担任全球财务规划和分析高级副总裁，也曾担任BD国际业务的副总裁和首席财务官。在2010年加入BD之前，Upadhyay先生在AstraZeneca PLC和Johnson & Johnson担任多个领导职务。Upadhyay先生在KPMG的公共会计部门度过了他职业生涯的早期。他还担任Vertex Pharmaceuticals Incorporated的董事会成员（2022年5月以来）。
- Suketu Upadhyay,Chief Financial Officer and Executive Vice President - Finance, Operations and Supply Chain of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, since July 2019;Senior Vice President, Global Financial Operations at Bristol-Myers Squibb from 2016 to June 2019;Executive Vice President and Chief Financial Officer of Endo International from 2013 to 2016;Previously served as interim Chief Financial Officer and Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of Becton Dickinson and Senior Vice President of Global Financial Planning and Analysis and Vice President and Chief Financial Officer of Becton Dickinson's international business;Previously held a number of global finance and strategy roles across AstraZeneca and Johnson & Johnson, including Research and Development, Supply Chain, Commercial Operations and Business Development;Spent the early part of his career in public accounting with KPMG, earning his CPA designation and his CMA designation (each designation currently inactive);Holds a Bachelor of Science in Finance from Albright College and an MBA from The Fuqua School of Business at Duke University.
- Wilfred van Zuilen
Wilfred van Zuilen 于 2021 年 6 月被任命为欧洲、中东和非洲总裁。在加入 Zimmer Biomet 之前，van Zuilen 先生曾在 Medtronic plc 担任过多个职务，包括 2020 年 10 月至 2021 年 5 月担任西北欧副总裁 2017 年 2 月至 2020 年 9 月担任欧洲、中东和非洲地区修复疗法集团副总裁，并于 2011 年 10 月至 2017 年 1 月担任外科解决方案集团欧洲先进外科技术副总裁。1998 年 1 月之前，他在 Medtronic plc 担任过其他职务，职责不断增加。 加入美敦力后，他在医疗销售领域工作了五年多，最近在 Baxter BV Edwards Life Sciences 任职。
Wilfred van Zuilen,was appointed Group President, Europe, Middle East and Africa in September 2023, after having served as President, Europe, Middle East and Africa since joining the Company in June 2021. He is responsible for the sales, marketing and distribution of products, services and solutions in the Europe, Middle East and Africa region. Prior to joining Zimmer Biomet, Mr. van Zuilen served in various roles for Medtronic plc, including as Vice President, North Western Europe from October 2020 to May 2021, as Vice President, Restorative Therapies Group EMEA from February 2017 through September 2020, and as Vice President, Advanced Surgical Technologies Europe, Surgical Solution Group, from October 2011 through January 2017. He served in other roles of increasing responsibility with Medtronic plc through January 1998. Before joining Medtronic, he spent more than five years in medical sales, most recently with Baxter BV (Edwards Lifesciences).- Wilfred van Zuilen 于 2021 年 6 月被任命为欧洲、中东和非洲总裁。在加入 Zimmer Biomet 之前，van Zuilen 先生曾在 Medtronic plc 担任过多个职务，包括 2020 年 10 月至 2021 年 5 月担任西北欧副总裁 2017 年 2 月至 2020 年 9 月担任欧洲、中东和非洲地区修复疗法集团副总裁，并于 2011 年 10 月至 2017 年 1 月担任外科解决方案集团欧洲先进外科技术副总裁。1998 年 1 月之前，他在 Medtronic plc 担任过其他职务，职责不断增加。 加入美敦力后，他在医疗销售领域工作了五年多，最近在 Baxter BV Edwards Life Sciences 任职。
- Wilfred van Zuilen,was appointed Group President, Europe, Middle East and Africa in September 2023, after having served as President, Europe, Middle East and Africa since joining the Company in June 2021. He is responsible for the sales, marketing and distribution of products, services and solutions in the Europe, Middle East and Africa region. Prior to joining Zimmer Biomet, Mr. van Zuilen served in various roles for Medtronic plc, including as Vice President, North Western Europe from October 2020 to May 2021, as Vice President, Restorative Therapies Group EMEA from February 2017 through September 2020, and as Vice President, Advanced Surgical Technologies Europe, Surgical Solution Group, from October 2011 through January 2017. He served in other roles of increasing responsibility with Medtronic plc through January 1998. Before joining Medtronic, he spent more than five years in medical sales, most recently with Baxter BV (Edwards Lifesciences).
- Lori Winkler
Lori Winkler 于 2020 年 3 月加入 Zimmer Biomet，担任集团人力资源副总裁，并于 2021 年 2 月被任命为高级副总裁兼首席人力资源官。在加入 Zimmer Biomet 之前，她曾在 Cardinal Health 担任人力资源全球副总裁。 从 2016 年 11 月到 2020 年 1 月，医疗部门。在加入康德乐之前，Winkler 女士在强生公司（包括其子公司 DePuy 和 Cordis）服务了 20 多年，最近从 2011 年 4 月到 11 月担任人力资源全球财务部全球主管 2016 年。
Lori Winkler,joined Zimmer Biomet as Group Vice President of Human Resources in February 2020 and was appointed Senior Vice President, Chief Human Resources Officer in March 2021. Prior to joining Zimmer Biomet, she served Cardinal Health, Inc. as a Worldwide Vice President of Human Resources in the Medical Segment from November 2016 through January 2020. Before joining Cardinal Health, Ms. Winkler served more than 20 years with Johnson and Johnson, including its subsidiary companies DePuy and Cordis, most recently as Global Head, Human Resources Global Finance from April 2011 through November 2016. She has served as an independent voting member of the board of directors of Family Promise, Inc., a 501(c)(3) charity focused on housing and homelessness, since August 2022.- Lori Winkler 于 2020 年 3 月加入 Zimmer Biomet，担任集团人力资源副总裁，并于 2021 年 2 月被任命为高级副总裁兼首席人力资源官。在加入 Zimmer Biomet 之前，她曾在 Cardinal Health 担任人力资源全球副总裁。 从 2016 年 11 月到 2020 年 1 月，医疗部门。在加入康德乐之前，Winkler 女士在强生公司（包括其子公司 DePuy 和 Cordis）服务了 20 多年，最近从 2011 年 4 月到 11 月担任人力资源全球财务部全球主管 2016 年。
- Lori Winkler,joined Zimmer Biomet as Group Vice President of Human Resources in February 2020 and was appointed Senior Vice President, Chief Human Resources Officer in March 2021. Prior to joining Zimmer Biomet, she served Cardinal Health, Inc. as a Worldwide Vice President of Human Resources in the Medical Segment from November 2016 through January 2020. Before joining Cardinal Health, Ms. Winkler served more than 20 years with Johnson and Johnson, including its subsidiary companies DePuy and Cordis, most recently as Global Head, Human Resources Global Finance from April 2011 through November 2016. She has served as an independent voting member of the board of directors of Family Promise, Inc., a 501(c)(3) charity focused on housing and homelessness, since August 2022.
- Paul Stellato
Paul Stellato，于2022年5月被任命为副总裁、财务总监和首席会计官。此前，他曾于2019年3月至2022年4月在全球水技术产品和服务提供商Xylem Inc.（“Xylom”）担任全球商业服务部财务副总裁。他于2011年10月从ITT公司（“ITT”）分拆后加入Xylem，并于2017年8月担任Xylem财务、财务规划和分析副总裁。自2016年8月起担任临时公司财务总监后，他于2017年8月晋升为副总裁、财务总监和首席会计官，并于2019年3月成为全球业务服务部财务副总裁。在2011年10月Xylem从ITT分拆之前，Stellato先生于2003年5月开始在ITT任职，最近担任过ITT的总审计师，在此之前担任过投资者关系经理。他在安永会计师事务所（Ernst&Young LLP）和安达信会计师事务所（Arthur Andersen LLP）开始公共会计职业生涯，是一名注册会计师。
Paul Stellato,was appointed Vice President, Controller and Chief Accounting Officer in May 2022. Previously, he served as Vice President Finance, Global Business Services from March 2019 through April 2022, with Xylem Inc. ("Xylem"), a global provider of water technology products and services. He joined Xylem upon its spinoff from ITT Corporation ("ITT") in October 2011 and served as Xylem's Vice President Finance, Financial Planning and Analysis through August 2017. He was promoted to Vice President, Controller and Chief Accounting Officer in August 2017 after serving as Interim Corporate Controller starting in August 2016, and became Vice President Finance, Global Business Services in March 2019. Prior to Xylem's spinoff from ITT in October 2011, Mr. Stellato served with ITT beginning in May 2003, having served most recently as ITT's General Auditor and prior to that, as Manager - Investor Relations. He began his career in public accounting with Ernst & Young LLP and Arthur Andersen LLP and is a certified public accountant.- Paul Stellato，于2022年5月被任命为副总裁、财务总监和首席会计官。此前，他曾于2019年3月至2022年4月在全球水技术产品和服务提供商Xylem Inc.（“Xylom”）担任全球商业服务部财务副总裁。他于2011年10月从ITT公司（“ITT”）分拆后加入Xylem，并于2017年8月担任Xylem财务、财务规划和分析副总裁。自2016年8月起担任临时公司财务总监后，他于2017年8月晋升为副总裁、财务总监和首席会计官，并于2019年3月成为全球业务服务部财务副总裁。在2011年10月Xylem从ITT分拆之前，Stellato先生于2003年5月开始在ITT任职，最近担任过ITT的总审计师，在此之前担任过投资者关系经理。他在安永会计师事务所（Ernst&Young LLP）和安达信会计师事务所（Arthur Andersen LLP）开始公共会计职业生涯，是一名注册会计师。
- Paul Stellato,was appointed Vice President, Controller and Chief Accounting Officer in May 2022. Previously, he served as Vice President Finance, Global Business Services from March 2019 through April 2022, with Xylem Inc. ("Xylem"), a global provider of water technology products and services. He joined Xylem upon its spinoff from ITT Corporation ("ITT") in October 2011 and served as Xylem's Vice President Finance, Financial Planning and Analysis through August 2017. He was promoted to Vice President, Controller and Chief Accounting Officer in August 2017 after serving as Interim Corporate Controller starting in August 2016, and became Vice President Finance, Global Business Services in March 2019. Prior to Xylem's spinoff from ITT in October 2011, Mr. Stellato served with ITT beginning in May 2003, having served most recently as ITT's General Auditor and prior to that, as Manager - Investor Relations. He began his career in public accounting with Ernst & Young LLP and Arthur Andersen LLP and is a certified public accountant.
- Rachel Ellingson
Rachel Ellingson于2018年4月被任命为高级副总裁兼首席战略官，并于2021年1月被任命为执行官。加入Zimmer Biomet之前，她曾担任St. Jude Medical的执行领导团队成员（2012年至2017年），最近担任战略副总裁（2015年至2017年）。在加入St. Jude Medical之前，她曾担任AGA Medical Corporation的业务发展和投资者关系副总裁。在加入AGA Medical之前，Ellingson女士拥有超过15年的投资银行经验，并在美国银行（Bank of America）担任医疗技术投资银行董事总经理。她自2021年4月起担任Biolife Solutions， Inc.的董事会成员，并担任其审计和薪酬委员会成员。
Rachel Ellingson,has served as a director and member of Biolife Solutions, Inc. Compensation Committee and Audit Committee since April 2021. Since March 2025, Ms. Ellingson has served as Chief Strategy and Corporate Development Officer at Solventum (NYSE: SOLV), a diversifie d medical device company. As a member of the executive leadership team at SOLV, Ms. Ellingson is responsible for global oversight of strategy, business development, integration, and divestitures. Prior to her appointment at SOLV, Ms. Ellingson served as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a medical device company focused in orthopedics from April 2018 to March 2025. Ms. Ellingson also served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical, Inc., a medical device company focused on cardiovascular and neuromodulation therapies, from 2011 to 2017. Before joining St. Jude Medical, Ms. Ellingson served as Vice President, Business Development and Investor Relations at AGA Medical Corporation, a developer and manufacturer of cardiovascular medical devices. Ms. Ellingson was an investment banker prior to her appointment at AGA Medical, serving as a Managing Director in the Healthcare Investment Banking sector of Bank of America Corporation (NYSE: BAC) and prior to that, was with Cowen & Company (NASDAQ: COWN). Ms. Ellingson holds an MBA in Finance from the University of Connecticut and a Bachelor of Arts degree from the University of Rhode Island.- Rachel Ellingson于2018年4月被任命为高级副总裁兼首席战略官，并于2021年1月被任命为执行官。加入Zimmer Biomet之前，她曾担任St. Jude Medical的执行领导团队成员（2012年至2017年），最近担任战略副总裁（2015年至2017年）。在加入St. Jude Medical之前，她曾担任AGA Medical Corporation的业务发展和投资者关系副总裁。在加入AGA Medical之前，Ellingson女士拥有超过15年的投资银行经验，并在美国银行（Bank of America）担任医疗技术投资银行董事总经理。她自2021年4月起担任Biolife Solutions， Inc.的董事会成员，并担任其审计和薪酬委员会成员。
- Rachel Ellingson,has served as a director and member of Biolife Solutions, Inc. Compensation Committee and Audit Committee since April 2021. Since March 2025, Ms. Ellingson has served as Chief Strategy and Corporate Development Officer at Solventum (NYSE: SOLV), a diversifie d medical device company. As a member of the executive leadership team at SOLV, Ms. Ellingson is responsible for global oversight of strategy, business development, integration, and divestitures. Prior to her appointment at SOLV, Ms. Ellingson served as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a medical device company focused in orthopedics from April 2018 to March 2025. Ms. Ellingson also served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical, Inc., a medical device company focused on cardiovascular and neuromodulation therapies, from 2011 to 2017. Before joining St. Jude Medical, Ms. Ellingson served as Vice President, Business Development and Investor Relations at AGA Medical Corporation, a developer and manufacturer of cardiovascular medical devices. Ms. Ellingson was an investment banker prior to her appointment at AGA Medical, serving as a Managing Director in the Healthcare Investment Banking sector of Bank of America Corporation (NYSE: BAC) and prior to that, was with Cowen & Company (NASDAQ: COWN). Ms. Ellingson holds an MBA in Finance from the University of Connecticut and a Bachelor of Arts degree from the University of Rhode Island.
- Mark Bezjak
Mark Bezjak，于2023年9月被任命为美洲区总裁。作为美洲总裁，他负责北美和拉丁美洲的所有商业、下游营销和分销活动。他于2008年4月加入Zimmer Biomet Holdings, Inc.，担任企业销售总监，并在公司内担任越来越重要的职位，最近担任北美总裁（自2021年以来）。在Zimmer Biomet工作之前，他曾在Teleflex Incorporated担任多个职位，从区域销售代表到战略客户总监（2000年至2008年）。从1997年到2000年，他还担任米其林轮胎公司的各种销售代表职务。
Mark Bezjak,was appointed President, Americas in September 2023. As President, Americas, he oversees all commercial, downstream marketing and distribution activities in North America and Latin America. Mr. Bezjak joined Zimmer Biomet in April of 2008 as Director of Corporate Sales and has held roles of increasing importance within the Company, most recently serving as President, North America, since 2021. Prior to his work at Zimmer Biomet, Mr. Bezjak held multiple roles with Teleflex Incorporated ranging from a regional sales representative to Director of Strategic Accounts from 2000 to 2008. He also held various sales representative roles with Michelin Tire Company from 1997 to 2000.- Mark Bezjak，于2023年9月被任命为美洲区总裁。作为美洲总裁，他负责北美和拉丁美洲的所有商业、下游营销和分销活动。他于2008年4月加入Zimmer Biomet Holdings, Inc.，担任企业销售总监，并在公司内担任越来越重要的职位，最近担任北美总裁（自2021年以来）。在Zimmer Biomet工作之前，他曾在Teleflex Incorporated担任多个职位，从区域销售代表到战略客户总监（2000年至2008年）。从1997年到2000年，他还担任米其林轮胎公司的各种销售代表职务。
- Mark Bezjak,was appointed President, Americas in September 2023. As President, Americas, he oversees all commercial, downstream marketing and distribution activities in North America and Latin America. Mr. Bezjak joined Zimmer Biomet in April of 2008 as Director of Corporate Sales and has held roles of increasing importance within the Company, most recently serving as President, North America, since 2021. Prior to his work at Zimmer Biomet, Mr. Bezjak held multiple roles with Teleflex Incorporated ranging from a regional sales representative to Director of Strategic Accounts from 2000 to 2008. He also held various sales representative roles with Michelin Tire Company from 1997 to 2000.
- Kevin Thornal
Kevin Thornal，自2023年4月起担任Nevro Corp.的总裁兼首席执行官，并自2023年5月起担任其董事会成员，直到2025年4月被Globus Medical， Inc.收购完成。此前，他从2022年4月至2023年4月担任Hologic， Inc.（“Hologic”）的全球诊断解决方案集团总裁。从2014年到2023年4月，Thornal先生在Hologic担任多个领导职位，职责不断提升。在加入Hologic之前，从2004年到2014年，Thornal先生在Stryker Corp.担任销售、营销和业务发展方面的多个职位。
Kevin Thornal,served as President and Chief Executive Officer of Nevro Corp. from April 2023, and as a member of its Board of Directors from May 2023, until the completion of its acquisition by Globus Medical, Inc. in April 2025. He previously served as the Group President of Global Diagnostic Solutions at Hologic, Inc. ("Hologic") from April 2022 to April 2023. Mr. Thornal served in several leadership positions with increasing levels of responsibility at Hologic from 2014 to April 2023. Prior to Hologic, Mr. Thornal held several roles of increasing responsibility at Stryker Corp. from 2004 to 2014 in sales, marketing, and business development.- Kevin Thornal，自2023年4月起担任Nevro Corp.的总裁兼首席执行官，并自2023年5月起担任其董事会成员，直到2025年4月被Globus Medical， Inc.收购完成。此前，他从2022年4月至2023年4月担任Hologic， Inc.（“Hologic”）的全球诊断解决方案集团总裁。从2014年到2023年4月，Thornal先生在Hologic担任多个领导职位，职责不断提升。在加入Hologic之前，从2004年到2014年，Thornal先生在Stryker Corp.担任销售、营销和业务发展方面的多个职位。
- Kevin Thornal,served as President and Chief Executive Officer of Nevro Corp. from April 2023, and as a member of its Board of Directors from May 2023, until the completion of its acquisition by Globus Medical, Inc. in April 2025. He previously served as the Group President of Global Diagnostic Solutions at Hologic, Inc. ("Hologic") from April 2022 to April 2023. Mr. Thornal served in several leadership positions with increasing levels of responsibility at Hologic from 2014 to April 2023. Prior to Hologic, Mr. Thornal held several roles of increasing responsibility at Stryker Corp. from 2004 to 2014 in sales, marketing, and business development.
- Chad F. Phipps
Chad F. Phipps，2007年5月，他被任命为高级副总裁，总法律顾问兼秘书。他为公司的全球的法律事务，他担任董事会的秘书。他还负责监督公司合规，政府事务，企业市场推广及传讯及公共关系活动。从2005年12月至2007年5月，他担任助理总法律顾问兼公司秘书。在此之前，自2003年9月他担任协理律师和助理秘书。他加入齐默于2003年。
Chad F. Phipps,was appointed Senior Vice President, General Counsel and Secretary in May 2007. He has global responsibility for the Company's Legal Affairs and he serves as Secretary to the Board of Directors. Mr. Phipps also oversees the Company's Government Affairs activities. Previously, Mr. Phipps served as Associate General Counsel and Corporate Secretary from December 2005 to May 2007. He joined the Company in September 2003 as Associate Counsel and Assistant Secretary. Prior to joining the Company, he served as Vice President and General Counsel of L&N Sales and Marketing, Inc. in Pennsylvania and he practiced law with the firm of Morgan, Lewis & Bockius in Philadelphia, focusing on corporate and securities law, mergers and acquisitions and financial transactions.- Chad F. Phipps，2007年5月，他被任命为高级副总裁，总法律顾问兼秘书。他为公司的全球的法律事务，他担任董事会的秘书。他还负责监督公司合规，政府事务，企业市场推广及传讯及公共关系活动。从2005年12月至2007年5月，他担任助理总法律顾问兼公司秘书。在此之前，自2003年9月他担任协理律师和助理秘书。他加入齐默于2003年。
- Chad F. Phipps,was appointed Senior Vice President, General Counsel and Secretary in May 2007. He has global responsibility for the Company's Legal Affairs and he serves as Secretary to the Board of Directors. Mr. Phipps also oversees the Company's Government Affairs activities. Previously, Mr. Phipps served as Associate General Counsel and Corporate Secretary from December 2005 to May 2007. He joined the Company in September 2003 as Associate Counsel and Assistant Secretary. Prior to joining the Company, he served as Vice President and General Counsel of L&N Sales and Marketing, Inc. in Pennsylvania and he practiced law with the firm of Morgan, Lewis & Bockius in Philadelphia, focusing on corporate and securities law, mergers and acquisitions and financial transactions.